The company offers enabling technologies including imaging, navigation, and robotics (INR) solutions for assisted surgery, notably the ExcelsiusGPS platform, a robotic guidance system for minimally invasive and open procedures. In February 2023, Globus Medical acquired NuVasive in an all-stock deal valued at $3.1 billion, significantly expanding its portfolio and market reach. The company operates with an aggressive acquisition strategy combined with organic product innovation across implants, instruments, and software platforms.
Cyborg Score Rationale
Q3 2025 revenue came in at $769 million, up 22.9% year-on-year, with full-year guidance of $2.88 billion at the midpoint. Sales grew at an exceptional 29.3% compounded annual growth rate over the last five years. The company demonstrates strong execution, market dominance in orthopedic devices, and successful integration of major acquisitions.
Top Insights
Q3 2025 revenue beat estimates by 4.7%, with non-GAAP EPS of $1.18 beating consensus by 53.4%.
Founded in 2003, Globus' single-minded focus on advancing surgery has made it the fastest growing company in the history of orthopedics.
As of September 30, 2025, trailing 12-month revenue was $2.77 billion.
Globus Medical's annualized revenue growth over the last two years is 50.3%, above its five-year trend, suggesting recently accelerated demand.
Named Competitors
Zimmer Biomet — Orthopedic implants and surgical instruments
Integra LifeSciences — Orthopedic and neurosurgery solutions
Stryker — Orthopedic implants and robotic-assisted surgery
Johnson & Johnson — Orthopedic and medical device portfolio